Anti-GPC3 CAR T for Treating Patients With Advanced HCC

NCT02395250 | Completed Phase 1

• 1 other identifier: RJ-20150313
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (1)

• Adverse events attributed to the administration of the anti-GPC3 CAR T cells

  2 years

Study Arms (1)

anti-GPC3 CAR T

EXPERIMENTAL

Biological: anti-GPC3 CAR T

Interventions

anti-GPC3 CAR T BIOLOGICAL

Also known as: CAR T cells redirected to Glypican-3 in cancer cells

anti-GPC3 CAR T

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age of 18-70 years;
• Pathologically confirmed advanced hepatocellular carcinoma (HCC);
• ≥1 measurable target lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1);
• Tumor tissue positive for GPC3 expression per immunohistochemical staining (IHC) assay;
• Estimated survival \> 12 weeks;
• Child-Pugh grade A;
• ECOG performance score of 0-1;
• HBV-DNA \< 200 IU/mL if positive for HBsAg or HBcAb. Patients positive for HBsAg shall receive anti-viral treatment per "The guideline of prevention and treatment for chronic hepatitis B: a 2015 update";
• Have adequate venous access for apheresis or venous blood collection;
• White blood cells ≥ 2.5 x 109/L, platelet ≥ 60×109/L, haemoglobin ≥ 9.0 g/dL, lymphocyte ≥ 0.4×109/L
• Serum albumin ≥ 30 g/dL, serum lipase and amylase≤1.5 upper limit of normal (ULN), serum creatinine ≤ 1.5 ULN and endogenous creatinine clearance ≥ 40mL/min, ALT and AST ≤ 5 ULN, Serum total bilirubin ≤ 2.5 ULN, Prothrombin Time is less than 4s longer than normal;
• Negative serum pregnancy test within 14 days before CAR T infusion, and with willingness to use reliable contraceptive methods to avoid pregnancy until 12 months after CAR T infusions for females of childbearing age; Having undergone sterilization procedure or with willingness to use reliable contraceptive methods to avoid pregnancy for males with female partner of childbearing age during the study;
• Able to understand and sign the informed consent form

You may not qualify if:

• Pregnant or lactating female patients;
• Positive serum tests for HCV, HIV, or syphilis;
• Presence of HBV/HCV coinfection;
• Presence of any uncontrollable active infection, such as, but not limited to, active tuberculosis
• History of systemic administration of steroids (not including inhaled steroids), or other immunosuppressant drugs within 2 weeks before apheresis;
• History of allergy to immunotherapy and related drugs, or β-lactam antibiotics, or history of other severe allergy;
• History or current presence of hepatic encephalopathy;
• Presence of ascites with clinical significance that is defined as positive focused physical examination for ascites, or ascites that requires treatment intervention (not including any ascites shown on image examinations without the need for clinical intervention);
• ≥ 50% of normal liver occupied with HCC tumor tissue, or presence of tumor thrombus in the portal vein, or mesenteric vein, or inferior vena based on image analysis;
• Presence of HCC metastatic lesion in the central nervous system, or presence of other diseases of central nervous system with clinical significance;
• Presence of heart disease that requires treatment intervention, or poorly controlled hypertension (systolic pressure \> 160 mmHg, or diastolic pressure \> 100 mmHg);
• Presence of active auto-immune disease that requires immunosuppressant treatment;
• History of organ transplantation or currently on the waiting list for organ transplantation, including, but not limited to, liver transplantation;
• Anti-HCC therapies including, but not limited to, surgical resection, interventional therapy, radiation therapy, chemotherapy, and immunotherapy, within 2 weeks before apheresis;
• History of receiving anti-PD-1 or anti-PD-L1 monoclonal antibodies, or other immunotherapy;

Sponsors & Collaborators

• RenJi Hospital: lead

Study Sites (1)

Shanghai Cancer Institute

Xuhui, Shanghai Municipality, 200032, China

Location

Related Publications (1)

• Shi Y, Shi D, Chi J, Cui D, Tang X, Lin Y, Wang S, Li Z, Jin H, Zhai B. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy. Cancer Commun (Lond). 2023 Sep;43(9):1064-1068. doi: 10.1002/cac2.12472. Epub 2023 Jul 21. No abstract available.

  PMID: 37478283 DERIVED

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Bo Zhai, MD

  Renji

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 17, 2015
• First Posted: March 23, 2015
• Study Start: March 1, 2015
• Primary Completion: June 1, 2016
• Study Completion: November 1, 2018
• Last Updated: August 28, 2019

Record last verified: 2018-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)